Issue 11 - Mar 16, 2018
  • Do patients know best? Industry, NCI committing dollars to studying patient-reported outcomes

    Researchers are coming to the conclusion that cancer patients are the best authority on how therapies affect them.

    Over the past few years, about 20 NCI trials and over 125 industry studies have incorporated direct reports of symptomatic adverse events by cancer patients through an NCI program.

  • Conversation with the Cancer Letter

    Basch: Patient-reported outcomes data can make cancer drugs safer, more tolerable

    Fifteen years ago, when Ethan Basch started developing measures for aggregating patient-reported outcomes, many of his colleagues in oncology saw no promise in this enterprise.

  • Conversation with the Cancer Letter

    Porter: I can’t tell you how the Trump administration gets its budget numbers

    John Edward Porter, a long-time key Congressional appropriator and advocate for biomedical research, received the Research!America Legacy Award at an advocacy awards dinner March 14.

  • In Brief

    • President’s Cancer Panel calls for urgent action on drug prices
    • AACR launches initiative focused on health disparities in African-Americans
    • Aurora Health Care & UTHealth join  Strata Oncology
    • PRIMO Lara named deputy chair of SWOG
    • Fox Chase’s Engstrom receives lifetime achievement award for cancer prevention
    • Bellerjeau gets lifetime achievement award from blood and marrow transplant group
  • TCCL Logo

  • Trials and Tribulations

    Rare Cancers, Common Need

    Cancer immunotherapy, and in particular immune checkpoint blockade, has transformed oncology with the potential for durable responses even in patients with metastatic disease. To date, regulatory approvals and clinical trials have focused on the study of these agents in relatively more common tumor types, such as melanoma, non-small cell lung cancer, bladder cancer, and kidney cancer, amongst others.

  • Clinical Roundup

    • ASTRO issues updated clinical guideline for whole breast radiation therapy
    • Testicular cancer survivors need screening for long-term heart disease risk
  • Drugs and Targets

    • Erdafitinib gets Breakthrough Therapy designation for metastatic urothelial cancer
    • FDA grants priority review to Merck’s sBLA for Keytruda for advanced cervical cancer
Issue 10 - Mar 9, 2018
Issue 9 - Mar 2, 2018
Issue 8 - Feb 23, 2018
  • Conversation with the Cancer Letter

    His six-month “listening tour” almost over, Sharpless discusses his vision for NCI

    “The notion that cancer’s not one disease, but thousands of diseases is really starting to sink in, and the implications of that fact are being felt throughout [NCI], and it means we have to change how we do everything. I hope that the early days of the Sharpless administration will be remembered as a time when we really bought into that reality and did some things differently,” NCI Director Norman “Ned” Sharpless said in a conversation with The Cancer Letter.

  • Conversation with the Cancer Letter

    UT Health San Antonio’s link with MD Anderson goes live

    How does it work?

    The affiliation between UT Health San Antonio Cancer Center and MD Anderson Cancer Center became active on Feb. 20. “Administratively, the two institutions are distinct. Patients will be cared for by the physicians and nurses of the [San Antonio] Mays Cancer Center, but certainly the platform of the care that they’re being provided has been heavily informed and integrated with MD Anderson, based on their treatment templates and methodology,” Ruben Mesa, director of the Mays Cancer Center, said to The Cancer Letter.

  • In Brief

    • Frederick Schnell named to new post of COA medical director
    • Richard Barakat to lead Northwell Health cancer services, research
    • Denis Guttridge named director of MUSC Darby Children’s Research Institute, associate director at Hollings
  • TCCL Logo

  • Trials and Tribulations

    Diversity within Diversity: Lessons from the Latinos of South Texas

    Diversity is to be celebrated in our society as enriching our experiences, our cultures and the richness of our lives. Diversity within the context of cancer care and research has appropriately grown to include considerations of diversity of race, ethnic heritage, age, gender, and experiences.

  • Clinical Roundup

    • NEJM publishes Loxo’s larotrectinib clinical data
  • Drugs and Targets

    • FDA expands approval of Imfinzi to reduce the risk of NSCLC progressing
  • NCI Protocols

    NCI trials for February

    NCI approved the following clinical research studies last month.

Issue 7 - Feb 16, 2018
  • A confusing Valentine: White House proposes cutting NIH by 27 percent, and—at the same time—reverses the cut

    What a difference a week makes.

    Last week, advocates for biomedical research were bracing for another shutdown of the federal government and fearing that the president’s budget proposal for fiscal year 2019 would drastically slash NIH.

  • NCI Director’s Report

    Sharpless: NCI should increase funding for RPG pool to maintain success rates for R01s

    NCI may need to invest at least $125 million in new money in the Research Project Grant pool in 2018 if the institute plans on keeping the success rates for R01s comparable to 2017, said NCI Director Ned Sharpless.

  • In Brief

    • NCI’s Lowy and Schiller win Szent-Györgyi Prize
    • Aldape starts as chief of laboratory of pathology at the NCI
    • Aghajanian appointed as NRG Oncology Gynecologic Cancer Committee Chair
    • Hudson named co-chair of NRG Oncology Delivery Research Committee
    • AACR’s Cancer Today magazine launches new website

     

  • Funding Opportunities

    American Cancer Society Supports Early Career Clinicians’ Move into Clinical Science

    The American Cancer Society started a grant program to support early career clinicians aiming to become clinician scientists.

  • TCCL Logo

  • Trials and Tribulations

    A Cancer Patient’s War on Cancer

    Imagine a hospital ward 100 years from now. Will multi-drug resistant infections be as prominent as they are today? I suspect so, because as antibiotics evolve, so will the infectious diseases they target. It’s an arms race in which both sides have a capacity to learn and adapt. Not so cancer. Cancers can’t learn from each other. But cancer patients can. This profound imbalance in the capacity for learning is an advantage that all cancer patients share. It is our super power. And we barely use it.

  • Clinical Roundup

    • NCCN & ASCO provide joint guidance on side effects from checkpoint inhibitors
    • Phase II trial shows durvalumab active in recurrent or metastatic head and neck cancer
    • UW Carbone study finds caregiver spouses of cancer patients suffer untreated depression
  • Drugs and Targets

    • FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint
    • Roche to acquire Flatiron Health for $1.9 billion
    • BMS, Nektar form collaboration for CD122-biased agonist
    • Tivozanib gets NICE nod for first-line treatment of advanced RCC
Issue 6 - Feb 9, 2018
  • Dissenters in anti-tobacco movement cite National Academy report in claim that “e-cigarettes are saving lives.” Nope, the NAS report’s authors say

    A group of tobacco control advocates, one of whom receives money from Philip Morris International, issued a press release trumpeting that “E-Cigarettes are Saving Lives,” and attributed this conclusion to a recent report by the National Academy of Sciences, Engineering, and Medicine.

  • Conversation with the Cancer Letter

    NTRI’s Abrams: Smokers should use e-cigarettes if they can’t quit completely

    Withholding e-cigarettes as an alternative from smokers who are unable to quit equals supporting the continued use of conventional cigarettes, said David Abrams, a member of the National Tobacco Reform Initiative.

    “The main thing you want to get across with the NASEM report and others is that smokers should absolutely try to find an e-cigarette that works for them if they can’t quit completely,” said Abrams, professor, Department of Social and Behavioral Sciences at the New York University College of Global Public Health. “The public have been very much misled and wrongly believe that e-cigarettes would not help you quit.”

  • An Appreciation

    Cancer moves fast…and we have to move faster

    Jon M. Huntsman Sr. dared to eradicate cancer from the face of the earth. People thought he was crazy, but for someone who started out delivering fresh eggs as a boy to support his family, went on to invent and then manufacture the polystyrene egg carton, and built from scratch a $12 billion global chemical company with more than 12,000 employees, there was no holding him back. Jon was a dreamer, a risk-taker, a true visionary, and a man whose compassion for others knew no limits. He didn’t sleep. His life was dedicated to making the world a better place: a world without homelessness, a world without hunger, a world without cancer.

  • Congress passes two-year budget deal, paving the way toward giving NIH a $2 billion raise

    So, the federal government shut down while America slept, but it reopened after a five-and-a-half hour pause, by early morning Feb. 9. We’ve seen this dance before.

    However, in a move that is anything but yawn-inducing, Congress passed a budget deal that paves the way toward giving NIH a $2 billion raise and lifts the spending caps on defense and non-defense spending through March 2019.

  • CRUK names ten finalists for £20m Grand Challenge

    Cancer Research UK has shortlisted ten multidisciplinary, international teams for what amounts to the second leg of competition for Grand Challenge awards.

    Each of the teams will now receive £30,000 in seed funding to prepare up their applications for interviews later this year.

  • In Brief

    • Arap, Pasqualini named to leadership posts at Rutgers Cancer Institute of New Jersey at University Hospital in Newark
    • Dhodapkar named director of new Center for Cancer Immunology at Emory Winship
    • Oberstein named director of GI medical oncology at NYU Perlmutter Cancer Center  
    • Campbell joins Fox Chase Cancer Center Cancer Biology Program
    • IU gets $14 million gift to create program focused on symptom management
  • TCCL Logo

  • Clinical Roundup

    • In phase III study Tecentriq and Avastin reduced risk of disease worsening/death by 26 percent in advanced kidney cancer
    • Opdivo plus Yervoy meet PFS endpoint in phase III trial in frontline NSCLC
    • Tyme announces interim phase II data for SM-88 in prostate cancer at ASCO GU Symposium  
  • Drugs and Targets

    • FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer
    • Foundation Medicine and EORTC collaborate comprehensive genomic profiling
    • Abbott PathVysion HER-2 DNA Probe assay to be used in ANGLE study
Issue 5 - Feb 2, 2018
  • Like it or not, CMS policy aims to change everything in Next generation sequencing

    A policy now in the works at the Centers for Medicare and Medicaid Services will define settings where Medicare will pay for next generation sequencing.

    The health care funding agency will use FDA approval of NGS tests to determine whether these tests are covered outright, receive “coverage with evidence development,” or are denied coverage altogether.

  • Dear CMS, Here’s what I think about your NGS policy… Agency draft memo garners 315 comments

    The range of opinions reflected in the 315 comments CMS received on its proposal for Medicare payment for Next Generation Sequencing reflects the extent of controversy over the test.

  • Conversation with the Cancer Letter

    Miller: “Doctors and patients have confidence in knowing that a test has gone through FDA”

    Concurrent FDA approval and the establishment of Medicare coverage will propel Next generation sequencing squarely into the mainstream of oncology practice, said Vincent Miller, chief medical officer of Foundation Medicine Inc.

  • In Brief

    • Mays Family Foundation makes legacy gift of $30 million to UT Health San Antonio Cancer Center
    • Sylvester Comprehensive Cancer Center to build proton therapy program
    • Syapse partners with Seoul National University Hospital and Megazone
    • Buchholz named medical director at Scripps MD Anderson Cancer Center
    • Kati Stoermer named executive director NRG Oncology
    • James Wade joins Vibrent Health as chief medical informatics officer
    • SU2C announces $11 million multi-disciplinary research program
    • Chen, Bild, Kahn, Heisterkamp join City of Hope
    • New building expands inpatient care at Siteman Cancer Center
    • CancerCare raises nearly $665,000 to support patients affected by hurricanes
    • Cancer Support Community adds Digital Nonprofit MyLifeLine to its network
  • Funding Opportunities

    AACR announces AACR-J&J lung cancer innovation science grants

    The American Association for Cancer Research has launched the AACR-Johnson & Johnson Lung Cancer Innovation Science Grants.

    A total of $4.5 million will be made available in research funding. Three multi-institutional research teams that seek novel approaches to the prevention, interception, and cure of lung cancer will each be awarded up to $1.5 million over three years.

  • TCCL Logo

  • Trials and Tribulations

    Re: Drug Pricing My unsolicited advice to HHS Secretary Alex Azar

    Dear Mr. Azar:

    I am the leader of CancerCare, a national organization that provides free, professional support services to anyone affected by cancer. I’m writing this letter to offer some perspective regarding the plight of nearly 16 million U.S. cancer survivors, the many more who are family and care providers, and all of those who will be diagnosed in the coming years.

  • Clinical Roundup

    Trial shows durable remissions with Kymriah in children, young adults with r/r ALL

    Novartis has announced updated results from the pivotal ELIANA clinical trial of Kymriah (tisagenlecleucel), formerly CTL019, in relapsed or refractory (pediatric and young adult patients with B-cell acute lymphoblastic leukemia have been published in The New England Journal of Medicine. New data include longer-term follow-up and efficacy in 75 infused patients, analysis of expansion and persistence of Kymriah, and longer-term safety.

  • Drugs and Targets

    • FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS
    • Amgen receives CHMP positive opinion to add updated survival data to Kyprolis label
    • Syndax announces immuno-oncology collaboration with AstraZeneca
Issue 4 - Jan 26, 2018
Issue 3 - Jan 19, 2018
  • Guest Editorial

    A unique drug for each patient: a paradigm shift in cancer therapy

    The recent FDA approvals of a cell/gene therapy for patients with advanced B cell malignancies provide a glimpse into a paradigm shift in the treatment of hematologic and solid cancers, the creation of a new drug unique to each cancer patient.

  • News Analysis

    As government shutdown looms, don’t lose sight of bigger battle over appropriations, sequestration

    As the rancor in Washington continues to escalate from bickering to a war on many fronts, the deadline approaches for the end of a continuing resolution that keeps the federal government open until Jan. 19.

  • In Brief

    • Allison, Bax, Doudna and Chang receive NAS prizes
    • Kathy Albain receives first Huizenga Family Endowed Chair at Loyola University Chicago
    • ACS CAN: Cancer patients should be exempt from possible Medicaid work requirements
    • ACCC’s 2017 survey: cost of treatment is top threat to cancer program growth
  • TCCL Logo

  • Clinical Roundup

    • Blood test for eight cancer types provides framework for early detection
    • Study shows screening population for select genes is a cost-effective solution
    • Polygenic hazard score predicts when men develop prostate cancer
    • Exelixis and Ipsen announce phase III trial results of Cabozantinib in advanced hepatocellular carcinoma
  • Drugs and Targets

    • Foundation Medicine and Pfizer form partnership to develop companion diagnostics
    • FDA approves addition of overall survival data to Kyprolis
    • Novartis granted FDA Priority Review for Kymriah for adults with r/r DLBCL
  • CTEP Protocols

    NCI CTEP-Approved Trials for January

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

    For further information, contact the principal investigator listed.

Issue 2 - Jan 12, 2018
Page 3 of 2412345678910...20...Last »